Cell Therapy News

Healio provided comprehensive coverage of this year’s ASH Annual Meeting and Exposition.

The FDA granted regenerative medicine advanced therapy designation to FT516, a natural killer cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

The FDA approved abatacept in combination with a calcineurin inhibitor and methotrexate for prevention of acute graft versus host disease.

Second-line tisagenlecleucel conferred identical EFS as standard treatment for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, according to randomized phase 3 results presented at ASH Annual Meeting and Exposition.

Minimal residual disease status appeared to influence outcomes after chimeric antigen receptor T-cell therapy for high-risk chronic lymphocytic leukemia, according to study results.

Sixty percent of hematologist-oncologists believe chimeric antigen receptor T-cell therapies provide clinical value at their current price, according to survey results presented at ASH Annual Meeting and Exposition.

Second-line lisocabtagene maraleucel more than quadrupled EFS compared with standard therapy for patients with relapsed or refractory large B-cell lymphoma, according to study results presented at ASH Annual Meeting and Exposition.

Second-line therapy with axicabtagene ciloleucel conferred a fourfold increase in EFS compared with standard-of-care treatment for diffuse large B-cell lymphoma, according to results of a randomized phase 3 study.

The FDA cleared an investigational new drug application for CYNK-101, a natural killer cell therapy for the treatment of patients with advanced HER2/neu-positive gastric or gastroesophageal junction adenocarcinoma.

The American Society of Hematology will present this year’s ASH Outstanding Service Award to Peter Marks, MD, PhD.